Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis

Ohshima, Koichi; Karube, Kennosuke; Kawano, Riko; Tsuchiya, Takeshi; Suefuji, Hiroaki; Yamaguchi, Takahiro; Suzumiya, Junji; Kikuchii, Masahiro

doi:10.3892/ijo.25.3.605

Cited by 38 publications

(55 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 Identification of CXCL13 expression as a distinctive feature of angioimmunoblastic T-cell lymphoma may help to redefine this subtype of peripheral T-cell lymphoma, through recognition of histologic variants. CXCL13 expression was seen in two out of 20 cases (10%) of peripheral T-cell lymphoma, unspecified, similar to the 11% identified by DNA microarray study and reported by Ohshima et al 12 The two cases in our study displayed some of the histologic features of angioimmunoblastic T-cell lymphoma, but lacked proliferation of follicular dendritic cells. One case showed very limited expression of T-cell antigens, which would be very AITL, angioimmunoblastic T-cell lymphoma; PTCL-u, peripheral T-cell lymphoma, unspecified.…”

Section: Discussionsupporting

confidence: 90%

“…A recent DNA microarray study documented CXCL13 expression in angioimmunoblastic T-cell lymphoma, and a minor subset of other peripheral T-cell lymphomas. 12 The results of this and our previous study confirm expression of the chemokine CXCL13 within the T cells of angioimmunoblastic T-cell lymphoma, and also show that this feature distinguishes it from other nodal peripheral T-cell lymphomas as well as from lymph nodes showing paracortical lymphoid hyperplasia. As it has been shown that CXCL13 is differentially expressed in germinal center T-helper cells compared to other CD4-positive T-cell subsets, 8 this finding adds to the growing body of evidence that the germinal center T-helper cell is the cell of origin for angioimmunoblastic T-cell lymphoma.…”

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified

et al. 2006

View full text Add to dashboard Cite

The germinal center T-helper cell has been proposed as the cell of origin for angioimmunoblastic T-cell lymphoma. Our recent report of expression of CXCL13, a chemokine critical for germinal center formation and one of the most highly upregulated genes in the germinal center T-helper cell subset, in the majority of angioimmunoblastic T-cell lymphoma cases, provided further support for this theory. To determine the specifity of this marker for angioimmunoblastic T-cell lymphoma, we evaluated CXCL13 expression in 26 nodal-based peripheral T-cell lymphomas and 14 lymph nodes showing paracortical lymphoid hyperplasia. No significant paracortical CXCL13 staining was seen in the reactive lymph nodes. By WHO classification criteria, 20 of the lymphoma cases were considered peripheral T-cell lymphoma, unspecified, and six were reclassified as angioimmunoblastic T-cell lymphoma after immunohistochemical detection of disorganized follicular dendritic cell meshworks. Combining the results of our studies, 31 of 35 angioimmunoblastic T-cell lymphoma cases (89%) showed CXCL13 expression, in contrast to two out of 20 peripheral T-cell lymphoma, unspecified cases (10%). The two peripheral T-cell lymphoma, unspecified cases that were positive for CXCL13 showed a Lennert lymphoma-like histology. While these cases did not meet all histologic criteria for angioimmunoblastic T-cell lymphoma, they did show an increase in EBV-positive B cells, suggesting they may be histologic variants of angioimmunoblastic T-cell lymphoma. In conclusion, CXCL13 expression is a distinctive feature of angioimmunoblastic T-cell lymphoma, providing further support for the germinal center T-helper cell as the cell of origin for this neoplasm. Given its specificity when compared to cases of peripheral T-cell lymphoma, unspecified as well as paracortical lymphoid hyperplasia, it may be a useful marker in the diagnosis of angioimmunoblastic T-cell lymphoma.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 86%

Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified

et al. 2006

View full text Add to dashboard Cite

show abstract

“…These cells themselves express chemokine receptors and can respond to chemokine in an autocrine and/or paracrine mechanism (25). Many different cancers, including PTCL-NOS (26), have different profiles of chemokine and chemokine receptor expression, but CXCR4 is most commonly found.…”

Section: Ptcl-nos Tumor Profile Signaturementioning

confidence: 99%

Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures

Mahadevan

Spier²,

Croce

et al. 2005

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

To glean biological differences and similarities of peripheral T-cell lymphoma-not otherwise specified [PTCL-NOS] to diffuse large B-cell lymphoma (DLBCL), a transcriptosome analysis was done on five PTCL-NOS and four DLBCL patients and validated by quantitative real-time reverse transcription-PCR on 10 selected genes. Normal peripheral blood T cells, peripheral blood B cells, and lymph node were used as controls. The resultant gene expression profile delineated distinct ''tumor profile signatures'' for PTCL-NOS and DLBCL. Several highly overexpressed genes in both PTCL-NOS and DLBCL involve the immune network, stroma, angiogenesis, and cell survival cascades that make important contributions to lymphomagenesis. Inflammatory chemokines and their receptors likely play a central role in these complex interrelated pathways: CCL2 and CXCR4 in PTCL-NOS and CCL5 and CCR1 in DLBCL. Highly overexpressed oncogenes unique to PTCL-NOS are SPI1, STK6, a-PDGFR, and SH2D1A, whereas in DLBCL they are PIM1, PIM2, LYN, BCL2A1, and RAB13. Oncogenes common to both lymphomas are MAFB, MET, NF-kB2, LCK, and LYN. Several tumor suppressors are also down-regulated (TPTE, MGC154, PTCH, ST5, and SUI1). This study illustrates the relevance of tumor-stroma immune trafficking and identified potential novel prognostic markers and targets for therapeutic intervention.

show abstract

“…11 CCR4-expressing neoplastic T cells have been demonstrated in approximately 40% of patients with CTCL 12 and peripheral T-cell lymphoma (PTCL) 10,13 by immunohistochemistry or multicolor flow cytometry (MFC), and the interplay between CCR4 and its ligands may be involved in malignant T-cell trafficking and distant organ involvement. In certain T-cell neoplasms (eg, adult T-cell leukemia/lymphoma), the extent of expression of CCR4 by malignant T cells is related to the degree of skin involvement.…”

Section: Introductionmentioning

confidence: 99%

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

Duvic

Pinter‐Brown

Foss

et al. 2015

Blood

211

151

View full text Add to dashboard Cite

show abstract

Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis

Cited by 38 publications

References 0 publications

Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified

Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified

Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

Contact Info

Product

Resources

About